Pathfinder Cell Therapy, Inc.
PFND · OTC
12/31/2014 | 12/31/2013 | 12/31/2012 | 12/31/2011 | |
|---|---|---|---|---|
| Market Cap | $1 | $9 | $13 | $26 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $5 | $4 | $2 | $0 |
| Enterprise Value | $5 | $13 | $15 | $26 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -52.6% | 56.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | 31.5% | 56.1% | 64.4% |
| EBITDA | -$1 | -$2 | -$2 | -$4 |
| % Margin | – | -2,940.7% | -1,789.5% | -4,930.1% |
| Net Income | -$2 | -$2 | -$2 | -$19 |
| % Margin | – | -3,353.7% | -1,975.4% | -25,920.5% |
| EPS Diluted | -0.003 | -0.003 | -0.003 | -0.036 |
| % Growth | 7.4% | 20.6% | 90.6% | – |
| Operating Cash Flow | -$1 | -$2 | -$2 | -$2 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$1 | -$2 | -$2 | -$2 |